Format

Send to

Choose Destination
Drugs Today (Barc). 2017 Feb;53(2):89-102. doi: 10.1358/dot.2017.53.2.2589164.

Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.

Author information

1
University of Auckland School of Medical Sciences, Pharmacology & Clinical Pharmacology Auckland, New Zealand. dmpaton38@yahoo.ca.

Abstract

Deutetrabenazine is a derivative of tetrabenazine in which two trideuteromethoxy groups substitute two methoxy groups. The active metabolites of deutetrabenazine have a longer half-life than those of tetrabenazine, together with a greater overall absorption. However, the peak plasma concentrations are lower. Because of these pharmacokinetic differences, deutetrabenazine can be given twice daily, thus improving compliance. The lower peak concentrations may account for a lower incidence of some unwanted adverse effects. Unlike tetrabenazine, deutetrabenazine has no effect on the QT interval. Treatment with deutetrabenazine significantly improved chorea in Huntington's disease, the hyperkinetic features of tardive dyskinesia, and tics in Tourette syndrome. In all three conditions, deutetrabenazine produced an acceptable level of overall adverse effects without causing any severe adverse effects.

KEYWORDS:

Deutetrabenazine; Huntington's disease; Hyperkinetic disorders; Tardive dyskinesia; Tourette syndrome

PMID:
28387387
DOI:
10.1358/dot.2017.53.2.2589164
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Clarivate Analytics
Loading ...
Support Center